PARG and ovarian carcinoma: To better understand the molecular determinants of PARG inhibitor sensitivity, we took a multifaceted approach, analysing (a) model systems engineered to be PARGi sensitive via inhibition of TIMELESS, and (b) intrinsically sensitive ovarian cancer cells.